Trials / Active Not Recruiting
Active Not RecruitingNCT07313436
Extended Release Protein Dosing
VitaKey Extended Release Protein Dosing
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- VitaKey Inc. · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Extended release nutritional protein | Participants will consume a beverage with extended release protein. |
| OTHER | Control | Participants will consume a beverage with standard nutritional protein. |
| OTHER | Negative Dose | Participants will consume a beverage with 15g less extended release protein than either the low dose cohort or the high dose cohort. |
Timeline
- Start date
- 2025-11-17
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2026-01-02
- Last updated
- 2026-03-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07313436. Inclusion in this directory is not an endorsement.